John Oyler - BeiGene Executive CoFounder
| 688235 Stock | 181.33 0.05 0.03% |
Founder
John Oyler is Executive CoFounder of BeiGene
| Age | 56 |
| Address | 94 Solaris Avenue, Camana Bay, Cayman Islands, KY1-1108 |
| Phone | 345-949-4123 |
| Web | https://www.beigene.com |
John Oyler Latest Insider Activity
Tracking and analyzing the buying and selling activities of John Oyler against BeiGene stock is an integral part of due diligence when investing in BeiGene. John Oyler insider activity provides valuable insight into whether BeiGene is net buyers or sellers over its current business cycle. Note, BeiGene insiders must abide by specific rules, including filing SEC forms every time they buy or sell BeiGene'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John Oyler over a month ago Disposition of 428 shares by John Oyler of BeiGene at 234.2728 subject to Rule 16b-3 | ||
John Oyler over a month ago Disposition of 1452 shares by John Oyler of BeiGene at 236.3695 subject to Rule 16b-3 | ||
John Oyler over six months ago Disposition of tradable shares by John Oyler of BeiGene at 150.85 subject to Rule 16b-3 | ||
John Oyler over six months ago Disposition of 7924 shares by John Oyler of BeiGene at 154.2084 subject to Rule 16b-3 |
BeiGene Management Efficiency
The company has return on total asset (ROA) of (0.0958) % which means that it has lost $0.0958 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2322) %, meaning that it generated substantial loss on money invested by shareholders. BeiGene's management efficiency ratios could be used to measure how well BeiGene manages its routine affairs as well as how well it operates its assets and liabilities. At present, BeiGene's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 11.7 M, whereas Non Current Assets Total are forecasted to decline to about 1.1 B. BeiGene (688235) is traded on Shanghai Stock Exchange in China and employs 10,600 people. BeiGene is listed under Biotechnology category by Fama And French industry classification.Management Performance
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.0958 |
BeiGene Leadership Team
Elected by the shareholders, the BeiGene's board of directors comprises two types of representatives: BeiGene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BeiGene. The board's role is to monitor BeiGene's management team and ensure that shareholders' interests are well served. BeiGene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BeiGene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Oyler, Executive CoFounder | ||
| Xiaodong Wang, CoChairman CoFounder | ||
| Liza Heapes, Head Relations | ||
| Chan Lee, General VP | ||
| Wang Lai, Global RD | ||
| Titus Ball, VP Officer | ||
| Julia Wang, Executive Officer | ||
| Aaron Rosenberg, CFO Officer | ||
| Jason Radford, Senior Development | ||
| Yang Ji, Chief Officer | ||
| Jaspreet MD, Senior Strategy | ||
| Melika Davis, Clinical Head | ||
| Yan Qi, Senior China | ||
| Xiaobin Wu, President COO |
BeiGene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BeiGene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.0958 | ||||
| Profit Margin | (0.26) % | ||||
| Operating Margin | (0.14) % | ||||
| Current Valuation | 158.93 B | ||||
| Shares Outstanding | 115.06 M | ||||
| Shares Owned By Insiders | 4.16 % | ||||
| Shares Owned By Institutions | 32.81 % | ||||
| Price To Book | 10.07 X | ||||
| Price To Sales | 7.13 X |
Currently Active Assets on Macroaxis
When determining whether BeiGene is a strong investment it is important to analyze BeiGene's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact BeiGene's future performance. For an informed investment choice regarding BeiGene Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BeiGene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade BeiGene Stock refer to our How to Trade BeiGene Stock guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.